Renal Effects of Liraglutide Biosimilar Versus Reference Liraglutidein Indian Patients with Type 2 Diabetes: Post Hoc Findings from aPhase III Trial

Authors

  • Sanjay Choudhari General Manager - Medical Affairs (Chronic Cluster) at Glenmark Pharmaceuticals Limited, Mumbai, India Author
  • AK Das Prof. of Medicine and Endocrinology, MGMCRI, SBV. Pondicherry, India Author
  • VIJAY NEGALUR Director at Dr. Negalur’s Diabetes & Thyroid Specialties Centre, Thane, India Author
  • Shashank Josh Consultant in Endocrinology and Diabetology at Lilavati Hospital and Research Centre and Joshi Clinic, Mumbai, India Author
  • Saiprasad Patil Senior General Manager and Head of Global Medical Affairs (India Formulations) at Glenmark Pharmaceuticals Limited, Mumbai, India Author
  • Hanmant Barkate Group Vice President & Global Head of Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, India Author

DOI:

https://doi.org/10.47363/JONE/2026(6)152

Keywords:

Liraglutide Biosimilar, Blood Pressure, chronic kidney disease (CKD), eGFR

Abstract

Background: Chronic kidney disease is a common complication of type 2 diabetes mellitus (T2DM) and contributes substantially to cardiovascular morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including liraglutide, have demonstrated potential renal benefits in cardiovascular outcomes trials. Data on renal parameters with liraglutide biosimilars, particularly in Indian populations, remain limited.
Methods: This post hoc exploratory analysis evaluated renal parameters from a randomized Phase III trial comparing a liraglutide biosimilar with reference liraglutide in Indian patients with T2DM. Changes in estimated glomerular filtration rate (eGFR), serum creatinine, and blood pressure were assessed from baseline to week 24. Within-group and between-group comparisons were performed using unadjusted statistical analyses.
Results: A total of 241 participants with complete renal data were included (liraglutide biosimilar, n=123; reference liraglutide, n=118). Both treatment groups demonstrated statistically significant within-group improvements in eGFR and reductions in serum creatinine over 24 weeks. No statistically significant differences were observed between the biosimilar and reference liraglutide groups for eGFR or serum creatinine at week 24. Modest reductions in systolic and diastolic blood pressure were observed in both groups.
Conclusion: In this post hoc analysis, liraglutide biosimilar and reference liraglutide were associated with comparable short-term changes in eGFR and serum creatinine in patients with T2DM. Given the exploratory design, short duration of follow-up, and reliance on surrogate renal markers, these findings should be interpreted cautiously. Prospective studies with longer follow-up and comprehensive renal endpoints are required to further characterize renal outcomes with liraglutide biosimilars.

Author Biographies

  • Sanjay Choudhari, General Manager - Medical Affairs (Chronic Cluster) at Glenmark Pharmaceuticals Limited, Mumbai, India

    Sanjay Choudhari, General Manager - Medical Affairs (Chronic Cluster) at Glenmark Pharmaceuticals Limited, Mumbai, India.

  • AK Das, Prof. of Medicine and Endocrinology, MGMCRI, SBV. Pondicherry, India

    AK Das, Prof. of Medicine and Endocrinology, MGMCRI, SBV. Pondicherry, India.

  • VIJAY NEGALUR, Director at Dr. Negalur’s Diabetes & Thyroid Specialties Centre, Thane, India

    VIJAY NEGALUR, Director at Dr. Negalur’s Diabetes & Thyroid Specialties Centre, Thane, India.

  • Shashank Josh, Consultant in Endocrinology and Diabetology at Lilavati Hospital and Research Centre and Joshi Clinic, Mumbai, India

    Shashank Josh,Consultant in Endocrinology and Diabetology at Lilavati Hospital and Research Centre and Joshi Clinic, Mumbai, India.

  • Saiprasad Patil, Senior General Manager and Head of Global Medical Affairs (India Formulations) at Glenmark Pharmaceuticals Limited, Mumbai, India

    Saiprasad Patil,Senior General Manager and Head of Global Medical Affairs (India Formulations) at Glenmark Pharmaceuticals Limited, Mumbai, India.

  • Hanmant Barkate, Group Vice President & Global Head of Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, India

    Hanmant Barkate, Group Vice President & Global Head of Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, India.

Downloads

Published

2026-11-19